Latest News on RARE

Financial News Based On Company


Advertisement
Advertisement

Ultragenyx Pharmaceutical (RARE) Gains MHRA Momentum, Is A 36% Undervaluation Enough?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-pharmaceutical-rare-gains-mhra-momentum-is-a-36-u
Ultragenyx Pharmaceutical (RARE) is showing momentum after the UK MHRA accepted its Marketing Authorisation Application for UX111, a gene therapy for Sanfilippo syndrome Type A. Despite recent share price gains, the stock is still significantly down year-over-year. The company is currently valued at $16.70 against a fair value of $26.00, suggesting a 36% undervaluation, but some investors caution about structural inefficiencies.

RARE: 2027 profitability target backed by cost cuts, commercial growth and focused pipeline bets

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4639966:0-rare-2027-profitability-target-backed-by-cost-cuts-commercial-growth-and-focused-pipeline-bets/
Ultragenyx Pharmaceutical Inc. (RARE) aims for meaningful profitability by 2027, driven by cost-cutting measures, over $700 million in cash, and sustained commercial growth. Key product launches FAYUVI and GENGLYCOS are on track, with setrusumab and DTX301 representing significant pipeline opportunities. This information is based on the company's UBS Global Biopharma Conference 2026 Audio Transcript from November 16, 2026.

Is Ultragenyx Pharmaceutical (RARE) Fully Priced After The UX111 Review?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/is-ultragenyx-pharmaceutical-rare-fully-priced-after-the-ux1
Ultragenyx Pharmaceutical's stock has fallen significantly over the past five years, leading investors to question its current valuation relative to sales. The company's P/S ratio of 2.2x is lower than the biotech group's average, and a recent UK regulatory review of its UX111 gene therapy, along with ongoing setrusumab work, suggests potential shifts in its future revenue. While some analysts see the stock as undervalued, others believe its current price already reflects a bullish outcome based on profitability targets.

AQR reports shared voting power over 595,657 Ultragenyx (RARE) shares in ownership amendment.

https://www.stocktitan.net/sec-filings/RARE/schedule-13g-a-ultragenyx-pharmaceutical-inc-amended-passive-investme-79ce9cac7fd7.html
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have filed an amended beneficial-ownership report for Ultragenyx Pharmaceutical Inc. (RARE). Each entity reported beneficial ownership of 633,393 shares, representing 0.64% of the class. They also reported shared voting power over 595,657 shares and shared dispositive power over 633,393 shares.

Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $24.84, Implies 53% Upside

https://www.tradingview.com/news/tradingview:27313e5a3c8ef:0-ultragenyx-pharmaceutical-inc-stock-12-month-price-target-cut-to-24-84-implies-53-upside/
Ultragenyx Pharmaceutical Inc.'s average price target has been reduced from $25.35 to $24.84 by 19 analysts, with a range of $16 to $39 per share. This updated target suggests a potential upside of approximately 53% based on the Nov. 12 closing price. The consensus rating for RARE remains a "Buy" from 21 analysts.
Advertisement

Ultragenyx to Participate at Investor Conferences in London

https://www.globenewswire.com/news-release/2026/11/11/3400690/20739/en/ultragenyx-to-participate-at-investor-conferences-in-london.html
Ultragenyx Pharmaceutical Inc. announced its participation in upcoming investor conferences in London. Company executives, including the President and CEO, Chief Medical Officer, and Chief Financial Officer, will attend the UBS Global Biopharma Conference 2026 and the 2026 Jefferies Global Healthcare Conference to participate in fireside chats and host one-on-one meetings. Webcasts of the fireside chats will be available on the company's investor relations website.

Three Ultragenyx executives will join fireside chats at two conferences.

https://www.stocktitan.net/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-cet0p3msf5f0.html
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced its participation in two upcoming investor conferences in London: the UBS Global Biopharma Conference on November 16, 2026, and the Jefferies Global Healthcare Conference on November 17, 2026. CEO Emil Kakkis, Chief Medical Officer Eric Crombez, and CFO Howard Horn will host fireside chats and one-on-one meetings at both events. Live and archived webcasts of the fireside chats will be available on the company's investor relations website.

Ultragenyx Pharmaceutical (RARE) Could Be 38% Undervalued After UK UX111 Filing Progress

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-pharmaceutical-rare-could-be-38-undervalued-after
Ultragenyx Pharmaceutical (RARE) recently achieved a regulatory milestone with the UK's acceptance of its Marketing Authorisation Application for UX111 gene therapy for Sanfilippo syndrome Type A. Despite this progress, the company's shares have seen significant declines over the past 90 days and one year. Simply Wall St's analysis suggests RARE could be 38% undervalued with a fair value of $26.00, prompting a discussion on whether the market's current caution is justified given advancing assets and ongoing losses.

Mereo BioPharma Reports Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/09/3398354/0/en/mereo-biopharma-reports-third-quarter-2026-financial-results.html
Mereo BioPharma Group plc announced its financial results for the third quarter ended September 30, 2026, highlighting progress on its setrusumab and alvelestat programs. The company reported $26.1 million in cash and cash equivalents, expected to fund operations into late-2027, and a net loss of $5.9 million for the quarter. Mereo is actively engaging with regulators for setrusumab in osteogenesis imperfecta and refining the Phase 3 trial design for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease.

Ultragenyx is cutting about 20% of its staff while ending drug programs for Angelman and Wilson diseases

https://www.medicaldaily.com/ultragenyx-cuts-workforce-ends-angelman-wilson-programs-480930
Ultragenyx Pharmaceutical is reducing its workforce by approximately 20% (about 250 positions) and terminating its drug programs for Angelman syndrome and Wilson disease. These cuts, which are expected to save the company money in research and administrative costs, come months after the FDA approved two of its gene therapies for glycogen storage disease type Ia and Sanfilippo syndrome type A. The company aims for full-year profitability by 2027 and continues to advance other clinical programs.
Advertisement

Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Privium Fund Management B.V.

https://www.marketbeat.com/instant-alerts/filing-ultragenyx-pharmaceutical-inc-rare-shares-sold-by-privium-fund-management-bv-2026-11-07/
Privium Fund Management B.V. significantly reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 31.2% in the third quarter of 2026, selling 105,763 shares. This reduction comes as Ultragenyx reported a quarterly loss that missed estimates and revenue below consensus, despite year-over-year growth. Analyst opinions are mixed, with a "Hold" consensus rating and an average target price of $29.79, while the company's investigational Sanfilippo syndrome gene therapy is under UK regulatory review.

Where Does Ultragenyx Pharmaceutical (RARE) Value Sit After Cost Cuts?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/where-does-ultragenyx-pharmaceutical-rare-value-sit-after-co
Ultragenyx Pharmaceutical (RARE) has experienced a significant stock decline despite new drug approvals and cost-cutting measures. The company's stock trades at a Price/Sales (P/S) ratio of 2.2x, considerably below the biotech sector average, which aligns closely with the Fair Ratio model given recent gene therapy approvals and cost reductions. This suggests investors are cautious about the current sales base rather than applying a clear discount or premium.

Ultragenyx Submits Sanfilippo Gene Therapy Marketing Application in UK

https://www.genomeweb.com/business-news/regulatory/gnw-ultagenyx-sanfilippo-fayuvi-uk-20261106/
Ultragenyx Pharmaceutical has submitted a marketing application to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its gene therapy, UX111, designed to treat Sanfilippo syndrome. This submission marks a significant step towards potentially making the therapy available for patients in the UK. Sanfilippo syndrome is a rare, genetic metabolic disorder that primarily affects the brain and spinal cord.

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

https://finance.yahoo.com/healthcare/articles/ultragenyx-announces-marketing-authorisation-application-083000739.html
Ultragenyx announced that its Marketing Authorisation Application (MAA) for rebisufligene etisparvovec (UX111), an investigational gene therapy for Sanfilippo syndrome Type A (MPS IIIA), has been accepted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for review. This marks a significant regulatory step for the therapy, which aims to address a severe, progressive, and rare genetic disorder with limited current treatment options. The company is also working with the National Institute for Health and Care Excellence (NICE) to ensure potential NHS access for eligible children.

Ultragenyx Secures UK Review for Sanfilippo Gene Therapy

https://grafa.com/en/news/united-states/ultragenyx-ux111-uk-mhra-acceptance-sanfilippo-gene-therapy?utm_source=rss&utm_medium=feed
Ultragenyx Pharmaceutical (NASDAQ:RARE) has received acceptance from the UK's MHRA for its UX111 gene therapy marketing authorization application for Sanfilippo syndrome Type A. The company is coordinating its NICE assessment with the regulatory review and aims for a funding appraisal decision to follow marketing authorization. The European Medicines Agency has also begun its review of the application.
Advertisement

Children with Sanfilippo syndrome have limited treatment options. A therapy is under UK review.

https://www.stocktitan.net/news/RARE/ultragenyx-announces-the-marketing-authorisation-application-maa-for-9wxwj9gh9vlm.html
Ultragenyx announced that its investigational gene therapy, UX111 (rebisufligene etisparvovec), for Sanfilippo syndrome Type A, has been accepted for formal scientific review by the UK's MHRA. This marks an important step towards potential marketing authorization in the UK, with Ultragenyx also aligning the NICE evaluation for NHS funding to coincide with the regulatory review. The therapy aims to address the significant unmet medical need for children suffering from this rare, progressive, and fatal neurological disorder.

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

https://www.quantisnow.com/insight/ultragenyx-announces-the-marketing-authorisation-application-maa-for-its-investigational-6777653
Ultragenyx announced that its Marketing Authorisation Application (MAA) for UX111, an investigational gene therapy for Sanfilippo syndrome Type A, has been accepted for review by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 28, 2026. This acceptance initiates the formal scientific review process, but there is no guarantee of approval. The company plans to align the NICE evaluation with the MHRA review to determine clinical and cost-effectiveness for NHS funding.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $22.00 Price Target at Citigroup

https://www.marketbeat.com/instant-alerts/analyst-ultragenyx-pharmaceutical-nasdaq-rare-given-new-2200-price-target-at-citigroup-2026-11-05/
Citigroup has lowered its price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) from $32.00 to $22.00 but maintained a "buy" rating, implying a potential upside of 41.48%. This adjustment follows the company's third-quarter earnings report, which missed analyst estimates with a loss of $1.16 per share and revenue of $173 million. Despite mixed analyst views, Ultragenyx reaffirmed its 2027 profitability goal and announced the sale of two Priority Review Vouchers for $413 million.

Barclays maintains Ultragenyx Pharmaceutical at Overweight, lowers price target to $32 from $35

https://www.tradingview.com/news/tradingview:70dbc61bcf9cb:0-barclays-maintains-ultragenyx-pharmaceutical-at-overweight-lowers-price-target-to-32-from-35/
Barclays has reiterated its "Overweight" rating for Ultragenyx Pharmaceutical (RARE) but adjusted its price target down from $35 to $32, representing an 8.6% decrease. This new price target suggests an 86.5% upside from the stock's closing price of $17.16 on November 4. Other analysts recently provided price targets for Ultragenyx ranging from $17 to $34.

TD Cowen maintains Ultragenyx Pharmaceutical at Buy, raises price target to $19 from $18

https://www.tradingview.com/news/tradingview:8b419c50ea9ac:0-td-cowen-maintains-ultragenyx-pharmaceutical-at-buy-raises-price-target-to-19-from-18/
TD Cowen has reiterated its "Buy" rating for Ultragenyx Pharmaceutical (RARE) and increased its price target to $19 from $18, suggesting a 14.3% upside from the recent closing price. This move follows several other analyst actions on the company, with price targets ranging from $16 to $22 over the past 30 days.
Advertisement

Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions

https://uk.finance.yahoo.com/news/ultragenyx-pharmaceutical-rare-stock-looks-161211213.html
Ultragenyx Pharmaceutical (RARE) stock has experienced a significant decline over the past five years, leading to questions about its current valuation relative to sales. Despite upcoming regulatory decisions and restructuring efforts aimed at improving cash flow, the stock's price-to-sales (P/S) ratio of 2.3x suggests it is fairly valued compared to its growth profile and industry averages, indicating that the market is balancing both future potential and execution risks.

Ultragenyx cuts staff after another study fails

https://www.statnews.com/2026/11/04/biotech-news-ultragenyx-cuts-staff-after-another-study-fails/
Ultragenyx has initiated staff reductions following the failure of another clinical study. This news comes amidst broader discussions in the biotech sector, including a whistleblower lawsuit against Madrigal Pharma and the potential impact of a Democratic Congress on drugmakers and drug pricing policies. Additionally, Novo Nordisk has upgraded its annual guidance, driven by the strong performance of Wegovy.

Ultragenyx Sets 2027 Expense Targets as It Winds Down GTX-102

https://www.tokenpost.com/news/business/48733
Ultragenyx Pharmaceutical Inc. announced lower expense targets for 2027 and reaffirmed its forecast for full-year GAAP profitability, attributing the plan to a 20% workforce reduction and the wind-down of GTX-102 studies. The company expects full-year R&D expenses below $350 million and SG&A expenses below $375 million in 2027, with the R&D target being at least 50% below 2025 levels. These changes accompany a strategic shift towards commercial operations following recent FDA approvals for GENGLYCOS and FAYUVI.

Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs

https://www.benzinga.com/markets/earnings/26/11/62864158/ultragenyx-pushes-toward-profitability-in-2027-led-by-pruned-pipeline-layoffs
Ultragenyx Pharmaceutical Inc. announced significant expense reductions, including a 20% workforce reduction, and a shift in focus to commercial execution and a targeted R&D strategy, aiming for profitability by 2027. The company will discontinue its Wilson disease and Angelman syndrome trials due to insufficient data, while prioritizing the commercial launches of Genglycos and Fayuvi and reaffirming its 2026 sales guidance. This restructuring follows missed third-quarter estimates.

Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds

https://sg.finance.yahoo.com/news/ultragenyx-pharmaceutical-rare-recasts-story-111453537.html
Ultragenyx Pharmaceutical (RARE) is under scrutiny after receiving FDA approvals for two gene therapies, GENGLYCOS and FAYUVI, while simultaneously reducing its workforce by 20% and discontinuing two development programs. Despite recent positive share price movement, longer-term returns remain negative, sparking a debate about its valuation. Analysts and investors are weighing the new approvals and cost-cutting measures against continued annual losses and operational inefficiencies.
Advertisement

Ultragenyx Lays Off Staff, Ends Wilson Disease Gene Therapy Program

https://www.genomeweb.com/business-news/financial/layoffs/gnw-ultragenyx-layoffs-gene-therapy-end-20261104/
Ultragenyx has announced layoffs and the cessation of its Wilson disease gene therapy development program. The decision was reported on November 4, 2026. This move indicates a strategic shift for the biotechnology company.

RARE Maintained by Wedbush -- Price Target Lowered to $22.00

https://www.gurufocus.com/news/9170077/rare-maintained-by-wedbush-price-target-lowered-to-2200
Wedbush has maintained its "Neutral" rating for Ultragenyx Pharmaceutical Inc (RARE) but lowered its price target from $25.00 to $22.00, a 12% decrease. Despite a GF Value™ suggesting the stock is 63.9% undervalued, concerns about financial strength and ongoing profitability challenges persist. Insider selling activity also indicates a cautious outlook on the company's short-term prospects.

Ultragenyx shrinks workforce and axes assets to halve R&D spend

https://www.fiercebiotech.com/biotech/ultragenyx-shrinks-workforce-and-axes-assets-halve-rd-spend
Ultragenyx is implementing significant cost-cutting measures, including a 20% workforce reduction and the discontinuation of several drug development programs, to halve its annual R&D budget by 2027. This strategy aims to achieve profitability by 2027, focusing resources on commercial products and a more curated pipeline developed through measured preclinical spending and small deals. The cuts follow recent R&D setbacks, including the failure of a phase 3 Angelman syndrome trial and lackluster data for a Wilson's disease gene therapy.

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

https://www.globenewswire.com/news-release/2026/11/03/3394751/20739/en/ultragenyx-reports-third-quarter-2026-financial-results-announces-substantial-expense-reductions-and-reaffirms-profitability-in-2027.html
Ultragenyx announced its Q3 2026 financial results, with total revenue of $173 million. The company reported the FDA approval of two gene therapies, GENGLYCOS and FAYUVI, and substantial expense reductions, including a 20% headcount reduction, aiming for significant profitability in 2027. Despite a net loss of $118 million in Q3, Ultragenyx reaffirms its full-year 2026 revenue guidance and is focusing on commercial execution and targeted R&D investments.

Earnings call transcript: Ultragenyx misses Q3 2026 estimates as stock falls after hours

https://www.investing.com/news/transcripts/earnings-call-transcript-ultragenyx-misses-q3-2026-estimates-as-stock-falls-after-hours-93CH-4996896
Ultragenyx Pharmaceutical reported a wider-than-expected loss and lower-than-forecast revenue for Q3 2026, causing its stock to fall after hours despite securing FDA approvals for two new gene therapies, GENGLYCOS and FAYUVI. The company missed EPS and revenue estimates but reaffirmed 2026 revenue guidance and provided optimistic 2027 expense and profitability outlook, citing a significant workforce reduction and proceeds from Priority Review Voucher sales. Management discussed the strategic shift to a leaner operating model, focusing on commercial products and a smaller R&D footprint, while addressing analyst questions on pipeline programs and launch strategies for their new gene therapies.
Advertisement

Ultragenyx Pharmaceutical Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62849262/ultragenyx-pharmaceutical-q3-2026-earnings-call-transcript
Ultragenyx Pharmaceutical reported FDA approvals for Genglycose and FIUVI but faced a setback with GTX-102 Phase 3 data, leading to significant cost reductions and a workforce reduction of approximately 20%. The company reaffirmed its 2026 revenue guidance of $730 to $760 million and aims for GAAP net income profitability in 2027 by focusing on commercial product launches, reducing R&D and SG&A expenses, and terminating the UX701 program for Wilson disease. Despite challenges, Ultragenyx is committed to launching its new gene therapies and growing its existing product portfolio, supported by strengthened finances from the sale of two PRVs.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Issues Quarterly Earnings Results

https://www.marketbeat.com/instant-alerts/earnings-ultragenyx-pharmaceutical-nasdaq-rare-issues-quarterly-earnings-results-2026-11-03/
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported a quarterly loss of $1.16 per share and revenue of $173 million, both missing analyst estimates. Shares rose slightly in Tuesday's mid-day trading to $16.63. The company also saw insider activity, with CFO Howard Horn selling 7,066 shares to cover tax withholding on vested equity awards, while analysts maintain a consensus "Hold" rating with an average price target of $33.65.

Ultragenyx Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:723217:0-ultragenyx-q3-2026-earnings-call-is-live/
Ultragenyx (RARE) has commenced its quarterly earnings call for Q3 2026. During the call, executives will discuss the latest financial results and answer questions from Wall Street analysts. Investors and followers of RARE are encouraged to listen for management commentary on future demand, margins, and capital spending, as these discussions can significantly influence market sentiment.

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

https://sg.finance.yahoo.com/news/compared-estimates-ultragenyx-rare-q3-213002158.html
Ultragenyx (RARE) reported Q3 2026 revenue of $173 million, an 8.2% year-over-year increase, but missed the Zacks Consensus Estimate of $184.25 million. The company's EPS was -$1.16, slightly below the -$1.15 consensus estimate. Key product revenues like Dojolvi and Evkeeza showed strong year-over-year growth, while Crysvita revenue declined.

Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance

https://www.streetinsider.com/Earnings/Ultragenyx+Pharma+%28RARE%29+Misses+Q3+EPS+by+6c%3B+Offers+Guidance/27283342.html
Ultragenyx Pharma (RARE) reported a Q3 EPS miss, coming in at ($1.16) against an analyst estimate of ($1.10), and revenue of $173 million, below the consensus of $182.19 million. The company also provided FY2026 revenue guidance of $730-760 million, which is slightly below the consensus estimate of $760.2 million.
Advertisement

Ultragenyx: Q3 Earnings Snapshot

https://www.kvue.com/article/syndication/associatedpress/ultragenyx-q3-earnings-snapshot/616-604fb7cd-603b-4a03-8e13-a839c86fa974
Ultragenyx Pharmaceutical Inc. reported a Q3 loss of $118 million, or $1.16 per share, missing Wall Street expectations of a $1.15 per share loss. The biotechnology company also fell short on revenue, posting $173 million against an expected $184.3 million. This data was generated by Automated Insights using Zacks Investment Research.

Ultragenyx gets first Euro nod for rare disease drug Dojolvi

https://pharmaphorum.com/news/ultragenyx-gets-first-euro-nod-rare-disease-drug-dojolvi
Ultragenyx's rare disease drug Dojolvi, an oral liquid formulation of triheptanoin, has received conditional marketing authorization in the UK from the MHRA, marking its first approval in Europe. Dojolvi treats long-chain fatty acid oxidation disorders (LC-FAOD), a group of inherited metabolic conditions where the body cannot convert long-chain fatty acids into energy. While approved in the US in 2020 and launched in Japan this year, UK patients will still need to await a reimbursement decision from NICE, anticipated to begin in October 2027.

Ultragenyx Pharmaceutical Inc. (RARE) Seasonal returns chart

https://uk.finance.yahoo.com/quote/RARE/seasonality/
This article provides a seasonal returns chart for Ultragenyx Pharmaceutical Inc. (RARE), showing the average monthly price return from 2016 to 2026. It also includes current stock information, financial data, and a notice for an upcoming Q3 2026 earnings call.

Vanguard reports voting power over 62,161 Ultragenyx (RARE) shares alongside its passive stake.

https://www.stocktitan.net/sec-filings/RARE/schedule-13g-a-ultragenyx-pharmaceutical-inc-amended-passive-investme-7277b9c3351c.html
Vanguard Portfolio Management has reported a passive stake of 8.6% in Ultragenyx Pharmaceutical Inc. (RARE), beneficially owning 8,481,266 shares as of September 30, 2026. The filing indicates Vanguard holds sole voting power over 62,161 shares and sole dispositive power over all 8,481,266 shares. This Schedule 13G/A amendment details Vanguard's control over the shares, emphasizing its right to receive dividends or direct sale proceeds.

Ultragenyx granted conditional U.K. nod for Dojolvi

https://www.tradingview.com/news/seekingalpha:a82b9f70e094b:0-ultragenyx-granted-conditional-u-k-nod-for-dojolvi/
Ultragenyx Pharmaceutical has received conditional marketing authorization from the U.K. drug regulator for its rare disease therapy Dojolvi (triheptanoin) to treat long-chain fatty acid oxidation disorders (LC-FAOD). Dojolvi, which generated $96 million in revenue last year, will be available for adults and children in the U.K., with full marketing authorization contingent on the results of an ongoing pediatric study. LC-FAODs are rare metabolic diseases that impair the body's ability to convert fat into energy, leading to various health issues.
Advertisement

Ultragenyx's results-call replay will be available for three months.

https://www.stocktitan.net/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2026-financial-7ivm5is8u33d.html
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced it will host a conference call on November 3, 2026, to discuss its third-quarter financial results and provide a corporate update for the period ending September 30, 2026. The call is scheduled for 5:00 p.m. ET, with a live webcast and a replay available for three months on the company’s investor website. This announcement led to a positive market reaction, with RARE closing 2.69% higher the day after the news.

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

https://www.globenewswire.com/fr/news-release/2026/10/27/3389622/20739/en/ultragenyx-to-host-conference-call-for-third-quarter-2026-financial-results-and-corporate-update.html
Ultragenyx Pharmaceutical Inc. announced it will host a conference call on Tuesday, November 3, 2026, at 5:00 p.m. ET to discuss its financial results and corporate update for the quarter ending September 30, 2026. A live and replayed webcast will be available on the company's website. Ultragenyx focuses on developing and commercializing novel products for serious rare and ultra-rare genetic diseases.

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

https://www.globenewswire.com/news-release/2026/10/27/3389622/20739/en/ultragenyx-to-host-conference-call-for-third-quarter-2026-financial-results-and-corporate-update.html
Ultragenyx Pharmaceutical Inc. announced it will host a conference call on Tuesday, November 3, 2026, at 5:00 p.m. ET to discuss its financial results and corporate update for the quarter ending September 30, 2026. A live and replayed webcast of the call will be available on the company’s investor relations website, with the replay accessible for three months. Ultragenyx focuses on developing and commercializing novel products for serious rare and ultra-rare genetic diseases.

Ultragenyx Pharmaceutical (RARE) Set to Post Quarterly Earnings on Tuesday

https://www.marketbeat.com/instant-alerts/upcoming-ultragenyx-pharmaceutical-rare-set-to-post-quarterly-earnings-on-tuesday-2026-10-27/
Ultragenyx Pharmaceutical (RARE) is scheduled to release its Q3 2026 earnings after market close on Tuesday, November 3rd, with analysts projecting a loss of $1.10 per share and revenue of $182.49 million. The company's previous quarter surpassed expectations with a $0.90 loss per share and $214 million in revenue. Investor sentiment is mixed, holding a consensus "Hold" rating and an average price target of $33.65, despite the stock recently trading around $16.08, significantly down from its 52-week high.

Rare Disease Genome Editing Market Outlook Signals Expansion To $2.88 Billion Through 2030

https://www.openpr.com/news/4673402/rare-disease-genome-editing-market-outlook-signals-expansion
The rare disease genome editing market is projected to expand significantly, from $1.29 billion in 2025 to $2.88 billion by 2030, driven by advancements in gene editing tools, increased funding, and broader adoption of precision medicine. Key players like Regeneron Pharmaceuticals Inc. and CRISPR Therapeutics AG are focusing on next-generation therapeutic platforms, especially CRISPR-based systems, to treat previously untreatable genetic conditions. The market is segmented by technology (CRISPR, TALEN, ZFN), disease type, application, and end-user, reflecting diverse approaches in this rapidly evolving field.
Advertisement

Rare Disease Pharmaceutical Service Market Report Examines Industry Trends, Growth Drivers And Future Outlook

https://www.openpr.com/news/4673450/rare-disease-pharmaceutical-service-market-report-examines
The rare disease pharmaceutical service market is experiencing rapid growth, projected to reach $150.96 billion in 2026 with a 13.2% CAGR, and is expected to hit $245.14 billion by 2030. This expansion is driven by advancements in orphan drug development, increased outsourcing, and the adoption of digital platforms for clinical trials. Key players include Johnson & Johnson, Merck, and Pfizer, with emerging trends focusing on innovative treatment strategies and integrated patient-centric care models.

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

https://www.manilatimes.net/2026/10/28/tmt-newswire/globenewswire/ultragenyx-to-host-conference-call-for-third-quarter-2026-financial-results-and-corporate-update/2455541/amp
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Tuesday, November 3, 2026, at 5:00 p.m. ET. The call will discuss the company's financial results and a corporate update for the quarter ending September 30, 2026. A live and replayed webcast will be available on the company's investor relations website.

Ultragenyx Pharmaceutical Inc. Estimates – NASDAQ:RARE

https://www.tradingview.com/symbols/NASDAQ-RARE/financials-estimates/
This article provides an overview of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing comparison of actual results with average, high, and low estimates and visualization of trends over time. The content primarily serves as a gateway to financial tools and data for investors.

Ultragenyx Pharmaceutical, Inc. Estimates – HAM:UP0

https://www.tradingview.com/symbols/HAM-UP0/financials-estimates/
This article provides financial estimates and actuals for Ultragenyx Pharmaceutical, Inc. (HAM:UP0), listed on the Hamburg Stock Exchange. It offers an overview of the company's financial data, including income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare reported results with analyst estimates. The data is available on TradingView, which aggregates information from various financial data providers.

Form DEF 14A Ultragenyx Pharmaceutical Inc For: 21 October By Investing.com

https://au.investing.com/news/stock-market-news/form-def-14a-ultragenyx-pharmaceutical-inc-for-21-october-93CH-4706100
This article from Investing.com announces the filing of Form DEF 14A by Ultragenyx Pharmaceutical Inc. for October 21. It mentions the company's stock symbol RARE and includes an image from Reuters, but provides no further details about the content of the filing. The rest of the content consists of general market data and news headlines from Investing.com.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement